Biotech Stocks Featured Penny Stock News Penny Stocks Watch List

5 Penny Stocks To Watch If You’re Concerned About Coronavirus

Sign up for our FREE Newsletter and get:

  • The Beginner’s Handbook For Trading Penny Stocks
  • Penny Stock Alerts And Ideas
  • Learn To Trade Penny Stocks
  • Free Access to The Fastest Growing Highest Rated Trading Chatroom

Coronavirus Penny Stocks #1: Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (INO – Free Report) was actually one of the penny stocks to watch during the last quarter of 2019. Shares ended up jumping from 52-week lows of $1.92 to highs this week of $4.70. Inovio Pharmaceuticals focuses mainly on DNA medicines to treat/cure/protect people from certain diseases.

Aside from HPV and cancer, infectious diseases are a target of the company. The company has collaborated with the likes of ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, GeneOne Life Science, the National Cancer Institute and many more.

[Read More] 5 Blockchain Penny Stocks to Buy? Take a Look At These

Aside from just having a keyword associated with it, Inovio was selected by the Coalition for Epidemic Preparedness Innovations this week. The Coalition grated the company “up to $9 million” to develop a vaccine against the new strain of coronavirus. It will support INO’s preclinical and clinical development into Phase 1 human testing. Inovio’s INO-4800 became its new coronavirus vaccine matched to the outbreak strain.

Furthermore, Inovio and the Coalition have worked together in the past. It had awarded Inovio a grant of up to $56 million to develop vaccines against Lassa fever as well as MERS, which is another version of coronavirus.

By J. Samuel

As a trader and expert finance writer, I enjoy finding new and emerging trends that may have been overlooked by the average masses. If there's one thing that a trader or investor wants to know, it's how to use valuable data to their advantage. My expertise is in uncovering this data and compiling it into actionable information. As a professional finance writer, I've contributed to many of the top finance platforms and pride myself on researching factual, publicly available information and using that in all of my articles.

Leave a Reply

Your email address will not be published. Required fields are marked *